- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05163067
Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease
Combined Aerobic Exercise and Cognitive Training for Alzheimer's Disease Prevention in Seniors With Genetic Susceptibility Estimated by Polygenic Risk Models: Cognition and Neural Plasticity Effects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alzheimer's disease (AD) is the most common type of dementia and the leading cause of disability in people older than 65 years worldwide. However, there is no effective disease-modifying therapy currently. Therefore, improvement of cognitive function in people at risk and, potentially, prevention of cognitive decline has been gaining attraction.
Our previous research reported a model of a combination single nucleotide polymorphism (SNP) (rs3777215, rs234434, rs71352238, and rs4420638) can predict AD onset with high performance, which is useful to identify people at risk for AD and thus allows for timely treatment and prevention.
Both aerobic exercise and cognitive training have been demonstrated beneficial effects on cognition in subjects with AD and healthy populations. Moreover, the synergistic effects of the combination have been proven recently. However, the effect of combined aerobic exercise and cognitive training on seniors with genetic susceptibility for AD remains to be elucidated. Herein, this study aims to
- assess the effects of long-term combined aerobic exercise and cognitive training on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with single nucleotide polymorphism of rs3777215, rs234434, rs71352238, and rs4420638.
- confirm the predictive value of the SNP model for AD in a longitudinal setting.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Longfei Jia, MD,PhD
- Phone Number: +86 10 83199456
- Email: longfei@mail.ccmu.edu.cn
Study Locations
-
-
-
Beijing, China
- Xuanwu Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Mandarin-speaking subjects.
- Not clinically demented.
- Meeting the cutoff values of MMSE and CDR.
- With positive variation of rs3777215, rs234434, rs71352238, and rs4420638.
Exclusion Criteria:
- Had major neurologic diagnosis (e.g., Parkinson's disease, stroke, encephalitis, and epilepsy) or other condition that might impair cognition or confound assessments.
- Had a history of psychotic episodes or had major depression (Hamilton Depression Rating Scale score > 24 points).
- Had severe systemic diseases, such as tumors, cardiovascular or orthopedic disorder that can affect the ability to perform the proposed intervention tasks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined aerobic exercise and cognitive training program
|
Participants will take part in a combined aerobic exercise and cognitive training program.
The program will include moderate cycling exercise and cognitive game resolving at the same time.
The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
|
No Intervention: Standard health counseling at baseline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive function over time as assessed by the Montreal Cognitive Assessment (MoCA)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
MoCA will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 30, with higher values indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by Mini Mental State Examination (MMSE)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
MMSE will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 30, with higher values indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by Clinical Dementia Rating (CDR)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
CDR will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 18, with higher values indicating worse cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by Verbal Fluency Test
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
Verbal Fluency Test will be performed to evaluate the semantic memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce as many animals as possible within 1 minute.
The score is the number of animals, with higher scores indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by Digit Span Test-Forward and Backward
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
Digit Span Tests will be performed to evaluate the working memory of participants at the enrollment and year 1, year 3, year 5, year 7.
The total scores are twelve for each test, with higher values indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by Trail-Making Test Parts A and B (TMT-A and TMT-B)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
TMT-A and TMT-B will be performed to evaluate the executive function of participants at the enrollment and year 1, year 3, year 5, year 7. Scoring is based on time taken to complete the test (e.g., 35 seconds yielding a score of 35), with lower scores indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by Boston Naming Test (BNT)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
BNT will be performed to evaluate the language function of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 30, with higher values indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by the Rey-Osterrieth Complex Figure Test (ROCF)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
ROCF will be performed to evaluate the visuospatial function and other cognition domains of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce a complicated line drawing, with higher scores indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in cognitive function over time as assessed by California Verbal Learning Test (CVLT)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
CVLT will be performed to evaluate the memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to finish immediate recall, delayed recall, and delayed recognition tasks in the test, with higher scores indicating better cognition.
|
baseline time, year 1, year 3, year 5, year 7
|
The area under curve of the SNP model (rs3777215, rs234434, rs71352238 and rs4420638) for the accurate diagnosis of AD
Time Frame: up to 7 years
|
The area under curve is used to show the ability of the SNP model (rs3777215, rs234434, rs71352238 and rs4420638) to diagnose AD.
The value of area under curve is higher, then the ability of the SNP model to diagnose AD is stronger.
|
up to 7 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in whole brain volume as accessed by brain MRI
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
Brain MRI will be performed to evaluate the whole brain volume of participants at the enrollment and year 1, year 3, year 5, year 7. Whole brain volume is measured in mL and determined by Freesurfer analysis.
There is no defined maximum.
Zero is the theoretical minimum.
Greater number indicates larger brain volume.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in daily function over time as assessed by Activities of daily living (ADL)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
ADL will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 14 to 64, with lower values indicating better function.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in anxiety over time as assessed by Hamilton Anxiety Rating Scale (HAMA)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
HAMA will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 64, with higher values indicating more severe anxiety.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in depression over time as assessed by Hamilton Depression Scale (HAMD)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
HAMD will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 96, with higher values indicating more severe depression.
|
baseline time, year 1, year 3, year 5, year 7
|
Change in neuropsychiatric symptoms over time as assessed by Neuropsychiatric Inventory Questionnaire (NPI-Q)
Time Frame: baseline time, year 1, year 3, year 5, year 7
|
NPI-Q will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7.
The score ranges from 0 to 144, with higher values indicating more severe neuropsychiatric symptoms.
|
baseline time, year 1, year 3, year 5, year 7
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Longfei Jia, MD,PhD, Xuanwu Hospital, Beijing
Publications and helpful links
General Publications
- Hill NT, Mowszowski L, Naismith SL, Chadwick VL, Valenzuela M, Lampit A. Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2017 Apr 1;174(4):329-340. doi: 10.1176/appi.ajp.2016.16030360. Epub 2016 Nov 14.
- Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, Tang Y, Qin Q, Wang F, Qiao Y, Shi S, Wang YJ, Du Y, Zhang J, Zhang J, Luo B, Qu Q, Zhou C, Gauthier S, Jia J; Group for the Project of Dementia Situation in China. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020 Jan;19(1):81-92. doi: 10.1016/S1474-4422(19)30290-X. Epub 2019 Sep 4.
- Lopez-Ortiz S, Valenzuela PL, Seisdedos MM, Morales JS, Vega T, Castillo-Garcia A, Nistico R, Mercuri NB, Lista S, Lucia A, Santos-Lozano A. Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. Ageing Res Rev. 2021 Dec;72:101479. doi: 10.1016/j.arr.2021.101479. Epub 2021 Sep 30.
- Jia L, Li F, Wei C, Zhu M, Qu Q, Qin W, Tang Y, Shen L, Wang Y, Shen L, Li H, Peng D, Tan L, Luo B, Guo Q, Tang M, Du Y, Zhang J, Zhang J, Lyu J, Li Y, Zhou A, Wang F, Chu C, Song H, Wu L, Zuo X, Han Y, Liang J, Wang Q, Jin H, Wang W, Lu Y, Li F, Zhou Y, Zhang W, Liao Z, Qiu Q, Li Y, Kong C, Li Y, Jiao H, Lu J, Jia J. Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain. 2021 Apr 12;144(3):924-937. doi: 10.1093/brain/awaa364.
- Ben Ayed I, Castor-Guyonvarch N, Amimour S, Naija S, Aouichaoui C, Ben Omor S, Tabka Z, El Massioui F. Acute Exercise and Cognitive Function in Alzheimer's Disease. J Alzheimers Dis. 2021;82(2):749-760. doi: 10.3233/JAD-201317.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICND20210820
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Combined aerobic exercise and cognitive training program
-
Xuanwu Hospital, BeijingNot yet recruiting
-
University of Maryland, BaltimoreRecruitingMild Cognitive ImpairmentUnited States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Maharishi Markendeswar University (Deemed to be...Not yet recruitingPolycystic Ovary Syndrome | Anti-Mullerian Hormone Deficiency | Female Infertility EndocrineIndia
-
Chang Gung Memorial HospitalUnknownStroke Patients With Cognitive DeclineTaiwan
-
Ankara Yildirim Beyazıt UniversityCompletedPhysical TherapyTurkey
-
Riphah International UniversityCompleted
-
Universidad Miguel Hernandez de ElcheCompletedBariatric Surgery and Physical Activity
-
National Cheng Kung UniversityActive, not recruiting
-
Wonju Severance Christian HospitalRecruitingBreast CancerKorea, Republic of